Lack of cross-tolerance between U69,593 and bremazocine suggest κ-opioid receptor multiplicity in mice

Peter J. Horan, Frank Porreca

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The development of tolerance, and the possibility of cross-tolerance, to the κ-opioid receptor-mediated antinociceptive effects of U69,593 and bremazocine was studied in mice. U69,593 and bremazocine elicited dose-related and κ-receptor-mediated antinociception following i.c.v. administration to mice. After a 3 day treatment regimen (twice daily injections) with an approximate antinociceptive A90 dose (90 nmol, i.c.v.) of U69,593, tolerance developed as demonstrated by a 5.6-fold righrward shift of the U69,593 dose-response line. The i.c.v. dose-response line for bremazocine was unaltered in U69,593-tolerant mice. Pretreatment with an approximate antinociceptive A90 dose of bremazocine (30 nmol, i.c.v.) for 3 days also produced tolerance as shown by a greater than 15-fold rightward shift in the bremazocine antinociceptive dose-response line. The i.c.v. dose-response line for U69,593 was unaltered in bremazocine-tolerant mice. These data demonstrate that while tolerance develops to the antinociceptive effects of both U69,593 and bremazocine, a two-way lack of cross-tolerance can be demonstrated between these κ-agonists in this endpoint. These data suggest mechanistic differences in the antinociceptive effects of these κ-agonists. Such suggestions are consistent with antinociceptive action of these agonists at subtypes of κ-receptors.

Original languageEnglish (US)
Pages (from-to)93-98
Number of pages6
JournalEuropean Journal of Pharmacology
Volume239
Issue number1-3
DOIs
StatePublished - Aug 3 1993

Fingerprint

Opioid Receptors
bremazocine
Injections

Keywords

  • (Mouse)
  • Antinociception
  • Arylacetamides
  • Benzomorphans
  • κ-Opioid receptors

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Lack of cross-tolerance between U69,593 and bremazocine suggest κ-opioid receptor multiplicity in mice. / Horan, Peter J.; Porreca, Frank.

In: European Journal of Pharmacology, Vol. 239, No. 1-3, 03.08.1993, p. 93-98.

Research output: Contribution to journalArticle

@article{7253aad13286400ab307e30816303e8c,
title = "Lack of cross-tolerance between U69,593 and bremazocine suggest κ-opioid receptor multiplicity in mice",
abstract = "The development of tolerance, and the possibility of cross-tolerance, to the κ-opioid receptor-mediated antinociceptive effects of U69,593 and bremazocine was studied in mice. U69,593 and bremazocine elicited dose-related and κ-receptor-mediated antinociception following i.c.v. administration to mice. After a 3 day treatment regimen (twice daily injections) with an approximate antinociceptive A90 dose (90 nmol, i.c.v.) of U69,593, tolerance developed as demonstrated by a 5.6-fold righrward shift of the U69,593 dose-response line. The i.c.v. dose-response line for bremazocine was unaltered in U69,593-tolerant mice. Pretreatment with an approximate antinociceptive A90 dose of bremazocine (30 nmol, i.c.v.) for 3 days also produced tolerance as shown by a greater than 15-fold rightward shift in the bremazocine antinociceptive dose-response line. The i.c.v. dose-response line for U69,593 was unaltered in bremazocine-tolerant mice. These data demonstrate that while tolerance develops to the antinociceptive effects of both U69,593 and bremazocine, a two-way lack of cross-tolerance can be demonstrated between these κ-agonists in this endpoint. These data suggest mechanistic differences in the antinociceptive effects of these κ-agonists. Such suggestions are consistent with antinociceptive action of these agonists at subtypes of κ-receptors.",
keywords = "(Mouse), Antinociception, Arylacetamides, Benzomorphans, κ-Opioid receptors",
author = "Horan, {Peter J.} and Frank Porreca",
year = "1993",
month = "8",
day = "3",
doi = "10.1016/0014-2999(93)90980-V",
language = "English (US)",
volume = "239",
pages = "93--98",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Lack of cross-tolerance between U69,593 and bremazocine suggest κ-opioid receptor multiplicity in mice

AU - Horan, Peter J.

AU - Porreca, Frank

PY - 1993/8/3

Y1 - 1993/8/3

N2 - The development of tolerance, and the possibility of cross-tolerance, to the κ-opioid receptor-mediated antinociceptive effects of U69,593 and bremazocine was studied in mice. U69,593 and bremazocine elicited dose-related and κ-receptor-mediated antinociception following i.c.v. administration to mice. After a 3 day treatment regimen (twice daily injections) with an approximate antinociceptive A90 dose (90 nmol, i.c.v.) of U69,593, tolerance developed as demonstrated by a 5.6-fold righrward shift of the U69,593 dose-response line. The i.c.v. dose-response line for bremazocine was unaltered in U69,593-tolerant mice. Pretreatment with an approximate antinociceptive A90 dose of bremazocine (30 nmol, i.c.v.) for 3 days also produced tolerance as shown by a greater than 15-fold rightward shift in the bremazocine antinociceptive dose-response line. The i.c.v. dose-response line for U69,593 was unaltered in bremazocine-tolerant mice. These data demonstrate that while tolerance develops to the antinociceptive effects of both U69,593 and bremazocine, a two-way lack of cross-tolerance can be demonstrated between these κ-agonists in this endpoint. These data suggest mechanistic differences in the antinociceptive effects of these κ-agonists. Such suggestions are consistent with antinociceptive action of these agonists at subtypes of κ-receptors.

AB - The development of tolerance, and the possibility of cross-tolerance, to the κ-opioid receptor-mediated antinociceptive effects of U69,593 and bremazocine was studied in mice. U69,593 and bremazocine elicited dose-related and κ-receptor-mediated antinociception following i.c.v. administration to mice. After a 3 day treatment regimen (twice daily injections) with an approximate antinociceptive A90 dose (90 nmol, i.c.v.) of U69,593, tolerance developed as demonstrated by a 5.6-fold righrward shift of the U69,593 dose-response line. The i.c.v. dose-response line for bremazocine was unaltered in U69,593-tolerant mice. Pretreatment with an approximate antinociceptive A90 dose of bremazocine (30 nmol, i.c.v.) for 3 days also produced tolerance as shown by a greater than 15-fold rightward shift in the bremazocine antinociceptive dose-response line. The i.c.v. dose-response line for U69,593 was unaltered in bremazocine-tolerant mice. These data demonstrate that while tolerance develops to the antinociceptive effects of both U69,593 and bremazocine, a two-way lack of cross-tolerance can be demonstrated between these κ-agonists in this endpoint. These data suggest mechanistic differences in the antinociceptive effects of these κ-agonists. Such suggestions are consistent with antinociceptive action of these agonists at subtypes of κ-receptors.

KW - (Mouse)

KW - Antinociception

KW - Arylacetamides

KW - Benzomorphans

KW - κ-Opioid receptors

UR - http://www.scopus.com/inward/record.url?scp=0027327168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027327168&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(93)90980-V

DO - 10.1016/0014-2999(93)90980-V

M3 - Article

VL - 239

SP - 93

EP - 98

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -